IceFORCE 2.1 CX 90 Cryoablation Needle
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $148.95 | 8 | 8 |
| 2023 | $30,000 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,000 | 2 | 99.5% |
| Food and Beverage | $148.95 | 8 | 0.5% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single Arm Phase 2 Study of Peri Operative Ipilimumab Nivolumab and Cryoablation in Women with Hormone Receptor Negative HER2 Negative Early StageResectable Breast Cancer | Boston Scientific Corporation | $30,000 | 0 |
Top Doctors Receiving Payments for IceFORCE 2.1 CX 90 Cryoablation Needle
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $30,000 | 2 |
| , MD, PHD | Vascular & Interventional Radiology | Columbus, OH | $38.16 | 1 |
| , MD | Vascular & Interventional Radiology | Scottsdale, AZ | $17.75 | 1 |
| Karrie Bargo | Registered Nurse | Scottsdale, AZ | $17.75 | 1 |
| , M.D | Body Imaging | Scottsdale, AZ | $17.75 | 1 |
| , M.D | Surgery | Mesa, AZ | $17.75 | 1 |
| , MD | Diagnostic Radiology | Atlanta, GA | $16.43 | 1 |
| , MD | Diagnostic Radiology | Baltimore, MD | $14.95 | 1 |
| , MD | Diagnostic Radiology | Wallingford, CT | $8.41 | 1 |
Manufacturing Companies
- Boston Scientific Corporation $30,149
Product Information
- Type Device
- Total Payments $30,149
- Total Doctors 8
- Transactions 10
About IceFORCE 2.1 CX 90 Cryoablation Needle
IceFORCE 2.1 CX 90 Cryoablation Needle is a device associated with $30,149 in payments to 8 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2023 to 2024. In 2024, $148.95 was paid across 8 transactions to 8 doctors.
The most common payment nature for IceFORCE 2.1 CX 90 Cryoablation Needle is "Unspecified" ($30,000, 99.5% of total).
IceFORCE 2.1 CX 90 Cryoablation Needle is associated with 1 research study, including "A Single Arm Phase 2 Study of Peri Operative Ipilimumab Nivolumab and Cryoablation in Women with Hormone Receptor Negative HER2 Negative Early StageResectable Breast Cancer" ($30,000).